ML-191 is primarily used in research settings as a selective inhibitor of the enzyme soluble epoxide hydrolase (sEH). This enzyme is involved in the metabolism of epoxyeicosatrienoic acids (EETs), which play a role in regulating inflammation, blood pressure, and pain. By inhibiting sEH, ML-191 helps to increase the levels of EETs, potentially offering therapeutic benefits in conditions such as hypertension, chronic pain, and inflammatory diseases. Its application is mostly confined to preclinical studies, where it aids in understanding the biological pathways and mechanisms related to sEH and EETs, paving the way for the development of new treatments for various cardiovascular and inflammatory disorders.